tissue microarray-FUR631
  • 点数:
    63
    例数:
    63
    点样直径(mm):
    2
    厚度(µm):
    5
    行数:
    7
    列数:
    9
    组织阵列类型:
    FFPE
    种属:
    Human
FUR631
加入收藏

描述: 子宫内膜癌组织芯片,附病理分级、TNM和临床分期,63例/63点

详情: 子宫内膜癌组织微阵列芯片,包含60例子宫内膜样腺癌及3例正常组织,一例一点

应用: Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page

备注

1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning.
2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.
In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers."

  • 说明书列表
  • 重复病例
  • 下载说明书
图表:
Uterus
  • Malignant(IA)
  • Malignant(IB)
  • Malignant(IIB)
  • Malignant(II)
  • Malignant(IIIA)
  • Malignant(IIIC)
  • NAT(*)
  • Normal(*)
  • _ma
组织芯片
FUR631
1
2
3
4
5
6
7
8
9
A
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
B
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
C
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
D
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
E
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
F
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
G
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
Ute
_ma
FUR631
  • 年龄:
  • 性别:
  • 器官/解剖部位:
  • 病理诊断:
  • 等级:
  • 分期:
  • 阶段:
  • 组织ID.:
  • 类型:
POS No. Age Sex Organ/Anatomic Site Pathology diagnosis Grade TNM Stage Type Tumor size
A1
1 35 F Uterus Endometrioid adenocarcinoma (sparse) 1 T2N0M0 II Malignant *
A2
2 57 F Uterus Endometrioid adenocarcinoma 1 T1aN0M0 IA Malignant *
A3
3 57 F Uterus Endometrioid adenocarcinoma (sparse) 1 T1bN0M0 IB Malignant *
A4
4 38 F Uterus Endometrioid adenocarcinoma 1 T1bN0M0 IB Malignant *
A5
5 49 F Uterus Endometrioid adenocarcinoma 1 T1aN0M0 IA Malignant 5*5
A6
6 47 F Uterus Endometrioid adenocarcinoma 1 T1bN0M0 IB Malignant 9*9
A7
7 56 F Uterus Endometrioid adenocarcinoma 1 T1aN0M0 IA Malignant 3*2.5*1.2
A8
8 53 F Uterus Endometrioid adenocarcinoma 1 T1aN0M0 IA Malignant 6*4*4
A9
9 54 F Uterus Endometrioid adenocarcinoma 1 T1aN0M0 IA Malignant 2.5*2*0.5
B1
10 50 F Uterus Endometrioid adenocarcinoma 1 T1bN0M0 IB Malignant 11*10*4
B2
11 37 F Uterus Endometrioid adenocarcinoma 1 T1bN0M0 IB Malignant 6*4.5*3
B3
12 53 F Uterus Endometrioid adenocarcinoma (sparse) 1 T1aN0M0 IA Malignant 9*8*8
B4
13 68 F Uterus Endometrioid adenocarcinoma 1 T1bN0M0 IB Malignant 7*4*4
B5
14 54 F Uterus Endometrioid adenocarcinoma 1 T1bN0M0 IB Malignant 2*1.5*1
B6
15 43 F Uterus Endometrioid adenocarcinoma 1 T1bN0M0 IB Malignant 8*7*6
B7
16 49 F Uterus Endometrioid adenocarcinoma 1 T1aN0M0 IA Malignant 2.5*1
B8
17 50 F Uterus Endometrioid adenocarcinoma 1 T1aN0M0 IA Malignant 4*2
B9
18 43 F Uterus Endometrioid adenocarcinoma 1 T1aN0M0 IA Malignant 2*2
C1
19 53 F Uterus Endometrioid adenocarcinoma 1 T2N0M0 II Malignant 9*9*4
C2
20 37 F Uterus Endometrioid adenocarcinoma 1 T1bN0M0 IB Malignant 4*3*1.5
C3
21 33 F Uterus Endometrioid adenocarcinoma 1--2 T1bN0M0 IB Malignant 11*9*4
C4
22 56 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 5*3.5
C5
23 70 F Uterus Endometrioid adenocarcinoma 2 T1bN1M0 IIIC Malignant 6*4*4
C6
24 52 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 4*3*2
C7
25 46 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 3.5*2*0.8
C8
26 61 F Uterus Endometrioid adenocarcinoma 2 T2N0M0 II Malignant 3*2
C9
27 70 F Uterus Endometrioid adenocarcinoma 2 T1aN0M0 IA Malignant 9*3.5*2.5
D1
28 30 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant *
D2
29 57 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant *
D3
30 52 F Uterus Endometrioid adenocarcinoma 2 T1aN0M0 IA Malignant *
D4
31 58 F Uterus Endometrioid adenocarcinoma (sparse) 2 T1aN0M0 IA Malignant *
D5
32 46 F Uterus Endometrioid adenocarcinoma 2 T1aN0M0 IA Malignant *
D6
33 74 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 3*3*2
D7
34 59 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 8*3*2.5
D8
35 54 F Uterus Endometrioid adenocarcinoma 2 T2N0M0 II Malignant 2.5*2*1
D9
36 50 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 3*2
E1
37 70 F Uterus Endometrioid adenocarcinoma 2 T2N0M0 II Malignant 1.5*4.5*2
E2
38 52 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 4*3*2
E3
39 68 F Uterus Endometrioid adenocarcinoma 2 T3aN0M0 IIIA Malignant 8*6*4
E4
40 54 F Uterus Endometrioid adenocarcinoma with necrosis 2 T1aN0M0 IA Malignant 9*5*3
E5
41 50 F Uterus Endometrioid adenocarcinoma 2 T3aN0M0 IIIA Malignant 6*4*2.5
E6
42 58 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 5*3*3
E7
43 43 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 7*3*3
E8
44 79 F Uterus Endometrioid adenocarcinoma 2 T1aN0M0 IA Malignant 4*3*0.8
E9
45 60 F Uterus Endometrioid adenocarcinoma 2 T1bN0M0 IB Malignant 5*5*3
F1
46 63 F Uterus Endometrioid adenocarcinoma with necrosis 2--3 T3aN0M0 IIIA Malignant 9*3*2.5
F2
47 58 F Uterus Endometrioid adenocarcinoma with necrosis 2--3 T1bN0M0 IB Malignant 10*9*7
F3
48 49 F Uterus Endometrioid adenocarcinoma 3 T2N0M0 II Malignant 5*5*4
F4
49 53 F Uterus Endometrioid adenocarcinoma 3 T3aN0M0 IIIA Malignant 7*6*4
F5
50 60 F Uterus Endometrioid adenocarcinoma 3 T1aN0M0 IA Malignant 4*3*2.5
F6
51 51 F Uterus Endometrioid adenocarcinoma 3 T1bN0M0 IB Malignant 8*4.5*4.5
F7
52 51 F Uterus Endometrioid adenocarcinoma 3 T3aN0M0 IIIA Malignant 4*3
F8
53 53 F Uterus Endometrioid adenocarcinoma 3 T1bN0M0 IB Malignant 4*2.5*1.5
F9
54 62 F Uterus Endometrioid adenocarcinoma 3 T1bN0M0 IB Malignant 3.5*3*1.2
G1
55 43 F Uterus Endometrioid adenocarcinoma with necrosis 3 T1bN0M0 IB Malignant 3.5*3*2.5
G2
56 66 F Uterus Endometrioid adenocarcinoma 3 T3aN0M0 IIIA Malignant *
G3
57 63 F Uterus Endometrioid adenocarcinoma 3 T1bN0M0 IB Malignant *
G4
58 55 F Uterus Endometrioid adenocarcinoma 3 T1bN0M0 IB Malignant *
G5
59 52 F Uterus Endometrioid adenocarcinoma 3 T2bN0M0 IIB Malignant *
G6
60 62 F Uterus Endometrioid adenocarcinoma 3 T1bN0M0 IB Malignant 3*2*1
G7
61 52 F Uterus Endometrial tissue * * * NAT *
G8
62 46 F Uterus Endometrial tissue * * * NAT *
G9
63 54 F Uterus Endometrial tissue * * * Normal *
_marker_
查找与该芯片存在重复病例的芯片:
如需了解产品规格方面的任何问题,请联系我们
0.078666s